Coherus Bio (CHRS), Baxalta (BXLT) Announced CHS-0214 Met Primary Efficacy Endpoints in Phase 3 Psoriasis Study
Tweet Send to a Friend
Coherus BioSciences, Inc. (NASDAQ: CHRS) and Baxalta Incorporated (NYSE: BXLT) today announced that CHS-0214, a proposed biosimilar of Enbrel® (etanercept) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
